Abstract
Urticaria and angioedema are common disorders. Chronic urticaria is defined as lasting longer than 6 weeks. Causes of chronic urticaria fall into the following categories: physical, allergic, hereditary, autoimmune, and idiopathic. Basophils and mast cells are the primary effector cells responsible for clinical symptoms and signs. These cells produce and secrete a variety of mediators including histamine, leukotrienes, prostaglandins, cytokines, chemokines, and other pro-inflammatory mediators. This leads to vasodilation, fluid exudation, increased vascular permeability, and accumulation of additional secondary inflammatory cells. Two mechanisms have been investigated as possibly contributing to the pathogenesis of chronic urticaria. One is the development of autoantibodies to FcεRI or IgE on mast cells and basophils. This appears to be responsible for 30–50 % of cases. The other is dysregulation of intracellular signaling pathways involving Syk, SHIP-1, or SHIP-2 in basophils and mast cells. The primary treatment for chronic urticaria is to treat the underlying pathology, if any can be identified. Otherwise, in idiopathic cases, H1 antihistamines, H2 antihistamines, antileukotrienes, and corticosteroids constitute the main pharmacologic treatment modalities. In severe and recalcitrant cases of chronic and autoimmune urticaria, immunosuppressive drugs have been used, most commonly cyclosporin. More recent experimental studies have also suggested that omalizumab, an anti-IgE therapy, may be of benefit. Currently, inhibitors of Syk are also being developed and tested in the laboratory and in animal models. As our understanding of the pathogenesis of idiopathic urticaria increases, development of additional drugs targeting these pathways may provide relief for the significant physical and psychological morbidity experienced by patients with this disorder.
Similar content being viewed by others
Notes
In this study, the authors did not distinguish between SHIP-1 and SHIP-2 values.
References
Greaves MW, Tan KT (2007) Chronic urticaria: recent advances. Clin Rev Allergy Immunol 33:134–143
Guldbakke KK, Khachemoune A (2007) Etiology, classification, and treatment of urticaria. Cutis 79:41–49
Saini SS (2009) Basophil responsiveness in chronic urticaria. Curr Allergy Asthm Rep 9:286–290
Crivellato E, Ribatti D (2010) The mast cell: an evolutionary perspective. Biol Rev 85:347–360
Zhang M, Murphy RF, Agrawal DK (2007) Decoding IgE Fc receptors. Immunol Res 37:1–16
Ali H (2010) Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett 128:36–45
Kaplan AP, Greaves M (2009) Pathogenesis of chronic urticaria. Clin Exp Allergy 39:777–787
Siracusa MC, Comeau MR, Artis D (2011) New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. Ann NY Acad Sci 1217:166–177
Falcone FH, Knol EF, Gibbs BF (2011) The role of basophils in the pathogenesis of allergic disease. Clin Exp Allergy 41:939–947
Siraganian RP, de Castro RO, Barbu EA, Zhang J (2010) Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS Lett 584:4933–4940
Bugajev V, Bambouskova M, Draberova L, Draber P (2010) What precedes the initial tyrosine phosphorylation of the high affinity IgE receptor in antigen-activated mast cell? FEBS Lett 584:4949–4955
Yamasaki S, Saito T (2008) Progress in allergy signal research on mast cells: signal regulation of multiple mast cell responses through FcεRI. J Pharmacol Sci 106:336–340
Saini SS, Paterniti M, Vasagar K, Gibbons SP, Sterba PM, Vonakis BM (2009) Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: relationship to expression of Syk and SHIP-2. Clin Immunol 132:342–348
Vonakis BM, Gibbons S, Sora R, Langdon JM, MacDonald SM (2001) Src homology 2 domain-containing inositol 5′ phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. J Allergy Clin Immunol 108:822–831
Vonakis BM, Vasagar K, Gibbons SP et al (2007) Basophil FcεRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 119:441–448
Vasagar K, Vonakis BM, Gober LM, Viksman A, Gibbons SP, Saini SS (2006) Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exper Allergy 36:770–776
Lezhoff A, Jasse RG, Denburg J, Dolovich J (1983) Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 119:636–640
Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP (1988) Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 90:213–217
Hide M, Francis DM, Grattan C, Hakimi J, Kochan JP, Greaves MW (1993) Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 328:1599–1604
Fiebiger E, Maurer D, Holub H et al (1995) Serum IgG autoantibodies directed against the α chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 96:2606–2612
Fiebiger E, Hammerschmid F, Stingl G, Mauere D (1998) Anti-FcεRIα autoantibodies in autoimmune-mediated disorders: identification of a structure–function relationship. J Clin Invest 101:243–251
Sabroe RA, Fiebiger E, Francis DM et al (2002) Classification of anti-FcεRIα and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 110:492–499
Mozena JD, Tinana A, Negri J, Steinke JW, Borish L (2010) Lack of a role for cross-reacting anti-thyroid antibodies in chronic idiopathic urticaria. J Invest Dermatol 130:1860–1865
Platzer MH, Grattan CEH, Poulsen LK, Skov PS (2005) Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients. Allergy 60:1152–1156
Alyasin S, Hamidi M, Karimi AA, Amiri A, Ghaffarpasand F, Ehsaei MJ (2011) Correlation between clinical findings and results of autologous serum skin test in patients with chronic idiopathic urticaria. Southern Med J 104:111–115
Kulthanan K, Jiamton S, Gorvanich T, Pinkaew S (2006) Autologous serum skin test in chronic idiopathic urticaria: prevalence, correlation and clinical implications. Asian Pac J Allergy Immunol 24:201–206
Khalaf AT, Li W, Jinquan T (2008) Current advances in the management of urticaria. Arch Immunol Ther Exp 56:103–114
Zuberbier T, Maurer M (2007) Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 87:196–205
Belsito DV (2010) Second-generation antihistamines for the treatment of chronic idiopathic urticaria. J Drugs Dermatol 9:503–512
Kapp A, Pichler WJ (2006) Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 45:469–474
Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A (2006) Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Brit J Dermatol 154:533–538
Staeveska M, Popov TA, Kralimarkova T et al (2010) The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 125:676–682
Hong JB, Lee HC, Hu FC, Chu CY (2010) A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria [letter]. J Am Acad Dermatol 63:e100–e102
Watson NT, Weiss EL, Harter PM (2000) Famotidine in the treatment of acute urticaria. Clin Dermatol 25:186–190
Moscati RM, Moore GP (1990) Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria. Ann Emerg Med 19:12–15
Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell SC (1992) Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med 21:237–242
Nettis E, D’Erasmo M, Di Leo E et al (2010) The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. Mediat Inflamm 2010:1–6
Drazen JM, Israel E, O’Bryne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197–206
Pacor ML, Di Lorenzo G, Corrocher R (2001) Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additives and/or acetylsalicylic acid. Clin Exper Allergy 31:1607–1614
Nettis E, Dambra P, D’Oronzio L, Loria MP, Ferrannini A, Tursi BA (2001) Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Clin Exp Dermatol 27:29–31
Erbagci Z (2002) The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 110:484–488
Nettis E, Colanardi MC, Paradiso MT, Ferrannini A (2004) Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 34:1401–1407
Di Lorenzo G, Pacor ML, Mansueto P et al (2004) Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 114:619–625
Asero R, Tedeschi A (2010) Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol 2:386–390
Grattan CEH, O’Donnell BF, Francis DM et al (2000) Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Brit J Dermatol 143:365–372
Barlow RJ, Black AK, Greaves MW (1993) Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol 3:273–275
Toubi E, Blant A, Kessel A, Golan TD (1997) Low dose cyclosporin A in treatment of severe chronic idiopathic urticaria. Allergy 52:312–316
Daher N, Lieberman P (2010) Immunosuppression medication as an approach to treat chronic urticaria in children. Curr Allergy Asthma Rep 10:1–2
Perez A, Woods A, Grattan CEH (2009) Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Brit J Dermatol 162:191–194
McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA (2006) Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 142:1337–1342
Reeves GEM, Boyle MJ, Bonfield J, Dobson P, Loewenthal M (2004) Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 34:182–186
Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK (2008) Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 122:569–573
Spector SL, Tan RA (2007) Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 99:190–193
Saavedra MC, Sur S (2011) Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy 9:2
Boers M (2011) Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis Rheum 63:329–330
Scott DL (2011) Role of spleen tyrosine kinase inhibitors in management of rheumatoid arthritis. Drugs 71:1121–1132
Riccaboni M, Bianchi I, Petrillo P (2010) Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 15:517–530
Mazuc E, Villoutreix BO, Malbec O et al (2008) A novel drug-like spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. J Allergy Clin Immunol 122:188–194
Villoutreix BO, Laconde G, Lagorce D, Martineau P, Miteva MA, Dariavach P (2011) Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening. PLoS One 6:e21117
Roquedes-Contios AM, Misery L (2011) What is intrinsic atopic dermatitis. Clin Rev Allergy Immunol 41:233–236
Liu FT, Goodarzi H, Chen HY (2011) IgE, mast cells, eosinophils and atopic dermatitis. Clin Rev Allergy Immunol 41:298–310
Misery L (2011) Therapeutic perspectives in atopic dermatitis. Clin Rev Allergy Immunol 41:267–271
Di Lorenzo G, Leto-Barone MS, La Piana S, Seidita A, Rini GB (2012) Chronic spontaneous urticaria: an autoimmune disease? A revision of the literature. Clin Exp Med. doi:10:1007/s10238-012-0188-3, E-pub ahead of print
Author information
Authors and Affiliations
Corresponding authors
Additional information
Katherine Altman is a medical student mentored by Dr. Christopher Chang
Rights and permissions
About this article
Cite this article
Altman, K., Chang, C. Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema. Clinic Rev Allerg Immunol 45, 47–62 (2013). https://doi.org/10.1007/s12016-012-8326-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-012-8326-y